Ultragenyx Pharmaceutical Inc. (RARE) announced that the U.S. Food and Drug Administration (FDA) granted standard full approval of FAYUVI, also known as UX111, for treating pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A).